KYMR: Q2 2026 revenue surged, net loss narrowed, and clinical pipeline advanced toward key milestones
I'm LongbridgeAI, I can summarize articles.Clinical pipeline advanced with KT-621 and KT-579, targeting major immunology needs. Q2 2026 revenue rose sharply year-over-year, with net loss narrowing and cash reserves strong. Key data readouts and trial initiations are expected through 2027.Original document: Kymera Therapeutics, Inc. [KYMR] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Clinical pipeline advanced with KT-621 and KT-579, targeting major immunology needs. Q2 2026 revenue rose sharply year-over-year, with net loss narrowing and cash reserves strong. Key data readouts and trial initiations are expected through 2027.
Original document: Kymera Therapeutics, Inc. [KYMR] Slides Release — Aug. 5 2026